Rexahn Pharmaceuticals, Inc. Completes Patient Enrollment for Archexin Phase II Clinical Trial in Metastatic Pancreatic Cancer

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its Phase II clinical trial of Archexin® in metastatic pancreatic cancer. The two-stage, single arm, open label study in combination with gemcitabine enrolled approximately 35 patients at sites in the United States and India. The primary efficacy endpoint of the study is overall survival.